



Market Announcement

11 May 2020

Mesoblast Limited (ASX: MSB) – Trading Halt

Description

The securities of Mesoblast Limited ('MSB') will be placed in trading halt at the request of MSB, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 13 May 2020 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)

11 May 2020

Ms Melissa Kostopoulos
Adviser, Listings Compliance (Melbourne)
ASX Compliance Pty Limited
Level 4 Rialto North Tower
525 Collins Street
Melbourne VIC 3000

Copy: tradinghaltsmelbourne@asx.com.au

Dear Melissa,


Request for trading halt for Mesoblast Limited (ASX: MSB)

Pursuant to ASX Listing Rule 17.1, Mesoblast Limited ACN 109 431 870 (ASX: MSB; NASDAQ: MESO) (the **Company**) requests a trading halt in its securities effective immediately pending an announcement by the Company in relation to a proposed equity financing.

For the purposes of Listing Rule 17.1, the Company provides the following information:

- (a) the trading halt is requested pending an announcement in relation to a proposed equity financing;
- (b) the Company requests that the trading halt continues until the earlier of it making an announcement regarding the matters above and the commencement of trading on Wednesday, 13 May 2020; and
- (c) the Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Yours sincerely



Charlie Harrison
Company Secretary
Mesoblast Limited

Corporate Headquarters
Level 38
55 Collins Street
Melbourne, Victoria 3000
AUSTRALIA

T +61 3 9639 6036
F +61 3 9639 6030

United States Operations
505 Fifth Avenue
Third Floor
New York, NY 10017
USA

T +1 212 880 2060
F +1 212 880 2061

Asia
20 Biopolis Way
#05-01 Centros
Biopreneur 3
SINGAPORE 138668

T +65 6570 0635
F +65 6570 0176

info@mesoblast.com
www.mesoblast.com